BRPI0911451A2 - biomarcadores para eficácia medicamentosa de egfr/her/erb - Google Patents

biomarcadores para eficácia medicamentosa de egfr/her/erb

Info

Publication number
BRPI0911451A2
BRPI0911451A2 BRPI0911451A BRPI0911451A BRPI0911451A2 BR PI0911451 A2 BRPI0911451 A2 BR PI0911451A2 BR PI0911451 A BRPI0911451 A BR PI0911451A BR PI0911451 A BRPI0911451 A BR PI0911451A BR PI0911451 A2 BRPI0911451 A2 BR PI0911451A2
Authority
BR
Brazil
Prior art keywords
erb
biomarkers
egfr
drug efficacy
efficacy
Prior art date
Application number
BRPI0911451A
Other languages
English (en)
Inventor
W Grunt Thomas
Shabbir Waheed
Original Assignee
Wyeth Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Wyeth Llc filed Critical Wyeth Llc
Publication of BRPI0911451A2 publication Critical patent/BRPI0911451A2/pt

Links

Classifications

    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/5011Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing antineoplastic activity
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/475Assays involving growth factors
    • G01N2333/485Epidermal growth factor [EGF] (urogastrone)
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/90Enzymes; Proenzymes
    • G01N2333/91Transferases (2.)
    • G01N2333/912Transferases (2.) transferring phosphorus containing groups, e.g. kinases (2.7)
    • G01N2333/91205Phosphotransferases in general
    • G01N2333/9121Phosphotransferases in general with an alcohol group as acceptor (2.7.1), e.g. general tyrosine, serine or threonine kinases

Landscapes

  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Biomedical Technology (AREA)
  • Immunology (AREA)
  • Hematology (AREA)
  • Chemical & Material Sciences (AREA)
  • Urology & Nephrology (AREA)
  • Molecular Biology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Analytical Chemistry (AREA)
  • Microbiology (AREA)
  • Biotechnology (AREA)
  • Toxicology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Food Science & Technology (AREA)
  • Medicinal Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Cell Biology (AREA)
  • Biochemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
BRPI0911451A 2008-05-25 2009-05-21 biomarcadores para eficácia medicamentosa de egfr/her/erb BRPI0911451A2 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US5601608P 2008-05-25 2008-05-25
PCT/US2009/044771 WO2009151908A1 (en) 2008-05-25 2009-05-21 Biomarkers for egfr/her/erbb drug efficacy

Publications (1)

Publication Number Publication Date
BRPI0911451A2 true BRPI0911451A2 (pt) 2019-09-24

Family

ID=41078344

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0911451A BRPI0911451A2 (pt) 2008-05-25 2009-05-21 biomarcadores para eficácia medicamentosa de egfr/her/erb

Country Status (4)

Country Link
AU (1) AU2009257802A1 (pt)
BR (1) BRPI0911451A2 (pt)
CA (1) CA2722890A1 (pt)
WO (1) WO2009151908A1 (pt)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2011087926A1 (en) * 2010-01-13 2011-07-21 Wyeth Llc A CUT-POINT IN PTEN PROTEIN EXPRESSION THAT ACCURATELY IDENTIFIES TUMORS AND IS PREDICTIVE OF DRUG RESPONSE TO A PAN-ErbB INHIBITOR

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AR056857A1 (es) * 2005-12-30 2007-10-24 U3 Pharma Ag Anticuerpos dirigidos hacia her-3 (receptor del factor de crecimiento epidérmico humano-3) y sus usos
EP1996193A2 (en) * 2006-03-13 2008-12-03 OSI Pharmaceuticals, Inc. Combined treatment with an egfr kinase inhibitor and an agent that sensitizes tumor cells to the effects of egfr kinase inhibitors
US20080108091A1 (en) * 2006-08-07 2008-05-08 Hennessy Bryan T Proteomic Patterns of Cancer Prognostic and Predictive Signatures

Also Published As

Publication number Publication date
AU2009257802A1 (en) 2009-12-17
WO2009151908A1 (en) 2009-12-17
CA2722890A1 (en) 2009-12-17

Similar Documents

Publication Publication Date Title
BRPI0920521A2 (pt) combinação farmacêutica
BRPI0919548A2 (pt) pacote para inserto
BRPI0912271A2 (pt) co-autoria estruturada
DK2310071T3 (da) Ekkogen medicinsk kanyle
DK2837348T3 (da) Kryokirurgiske fremgangsmåder
EP2307774A4 (en) PRESSURE RELIEF VALVE
EP2135921A4 (en) M-C-N-O-fluorescer
EP2377874A4 (en) Antioxidant
DK2300238T3 (da) Skyggebillede-sikkerhedstræk
BRPI0922884A2 (pt) compostos para tratamento de câncer
DK2310613T3 (da) Forbedret brudled til stigrør
BRPI0909287A2 (pt) Retenção
DK2271618T3 (da) Farmaceutiske forbindelser
EP2280264A4 (en) STANDARD AGENTS
BRPI0917718A2 (pt) calçado
AT507449A3 (de) Dämmstoffbefestiger
BRPI0916990A2 (pt) Combinações inseticidas
BRPI0913872A2 (pt) multi-bandagem
BRPI0918508A2 (pt) orto-aminoanilidas para o tratamento de câncer
BRPI0919750A2 (pt) transmissão
EP2320211A4 (en) SPECTROMETER
ITBS20080008A1 (it) Lampada
ITBS20080009A1 (it) Lampada
BRPI0911451A2 (pt) biomarcadores para eficácia medicamentosa de egfr/her/erb
ES1069163Y (es) Dispositivo de seguridad para guardarrailes

Legal Events

Date Code Title Description
B08F Application fees: dismissal - article 86 of industrial property law
B08K Lapse as no evidence of payment of the annual fee has been furnished to inpi (acc. art. 87)

Free format text: EM VIRTUDE DO ARQUIVAMENTO PUBLICADO NA RPI 2543 DE 01-10-2019 E CONSIDERANDO AUSENCIA DE MANIFESTACAO DENTRO DOS PRAZOS LEGAIS, INFORMO QUE CABE SER MANTIDO O ARQUIVAMENTO DO PEDIDO DE PATENTE, CONFORME O DISPOSTO NO ARTIGO 12, DA RESOLUCAO 113/2013.